Patents Examined by Taeyoon Kim
  • ADAMTS13-containing compositions having thrombolytic activity
    Patent number: 10233436
    Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: March 19, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH, Children's Medical Center Corporation
    Inventors: Denisa D. Wagner, Anil Kumar Chauhan, Friedrich Scheiflinger, Barbara Plaimauer
  • Cell-containing sheet
    Patent number: 10219888
    Abstract: In accordance with the present invention, an implant in which cells are arranged in a fine pattern that is available for immediate implantation and that does not need to be removed after implantation is provided. The present invention relates to a cell-containing sheet, which comprises cells and a support comprising a bioabsorbable material, in which the support has a cell adhesion protein-containing layer on the surface thereof and the cells form a pattern on the support.
    Type: Grant
    Filed: June 19, 2006
    Date of Patent: March 5, 2019
    Assignees: National University Corporation Tokyo Medical and Dental University, DAI NIPPON PRINTING CO., LTD.
    Inventors: Ikuo Morita, Akiko Kobayashi, Hideshi Hattori, Masatoshi Kuroda
  • Fabricating device of three-dimensional scaffold and fabricating method thereof
    Patent number: 10213967
    Abstract: A fabricating device of a three-dimensional (3-D) scaffold comprises a bubble generator, a bubble mixing channel, a coagulating solution channel and a bubble collector. The bubble generator includes a gas channel and a gel solution channel crossing the gas channel. The bubble mixing channel is connected with a first outlet of the bubble generator. The coagulating solution channel is connected with the bubble mixing channel. The bubble collector is connected with a second outlet of the bubble mixing channel.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: February 26, 2019
    Assignee: Academia Sinica
    Inventors: Keng-Hui Lin, Yi-Hsuan Lee
  • CD82-positive cardiac progenitor cells
    Patent number: 10208287
    Abstract: An object of the present invention is to provide a myocardial progenitor cell that is specifically induced to differentiate into a cardiomyocyte, and a method for preparing the myocardial progenitor cell. A method for preparing a CD82-positive cell includes, in sequence, a step (a) of obtaining stem cells, a step (b) of subjecting the stem cells to induction treatment of differentiation into cardiovascular cells, and a step (c) of separating, from the stem cells having been subjected to the induction treatment of differentiation in the step (b), a CD82-positive cell being negative for at least one cell surface marker selected from CD73, CD44, CD105, CD121a, CD18, and CD120a. This method enables preparation of a CD82-positive cell for use as a myocardial progenitor cell.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: February 19, 2019
    Assignee: iHeart Japan Corporation
    Inventors: Jun Yamashita, Masafumi Takeda
  • Preparation of a cell concentrate from a physiological solution
    Patent number: 10206950
    Abstract: The present invention is directed to methods and compositions regarding the preparation of an cell concentrate, such as, for example, an osteogenic cell concentrate, from a physiological solution, such as bone marrow aspirate, blood, or a mixture thereof. In specific embodiments, the invention provides methods and compositions utilizing two physiological solution-processing techniques, particularly in a point of care environment, wherein centrifugation is not employed.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: February 19, 2019
    Assignees: Smith & Nephew, Inc., Pall Corporation
    Inventors: Samuel O. Sowemimo-Coker, Marcus Lee Scott, Marc Long, Ed Margerrison, Michael B. Cooper
  • Treatment of migraine headaches with presynaptic neurotoxin
    Patent number: 10201497
    Abstract: The present invention provides a method for treating a patient for migraine headache, including symptoms associated with migraine head ache, such as migraine associated vertigo, which comprises administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin, e.g. Botulinum toxin in a pharmaceutically safe form.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 12, 2019
    Assignee: Miotox, LLC
    Inventor: William J. Binder
  • Compositions and methods for treating inflammatory related diseases or conditions using probiotics
    Patent number: 10195237
    Abstract: The present invention provides a method of treating a disease or condition characterized by inflammation in a subject in need thereof, comprising administering to the subject an effective amount of a Pediococcus acidilactici probiotic. Compositions of Pediococcus acidilactici probiotic are also provided.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: February 5, 2019
    Assignee: IMAGILIN TECHNOLOGY LLC
    Inventors: Jhy-Jhu Lin, Jolinta Lin
  • Procurement of placental stem cells
    Patent number: 10190092
    Abstract: Methods and solutions for the preservation and procurement of placental stem cells. A method for collecting stem cells from a placenta includes draining cord blood from the placenta and collecting the drained cord blood in a first collection. The drained placenta is perfused with a first perfusion solution including a placental preservative base solution and a vasodilator. The placenta is perfused with a second perfusion solution including placental preservative base solution, a stem cell releasing agent, an antibiotic, and an anticoagulant, and a predetermined amount of time is allowed to elapse as the first and second perfusion solutions perfuse the placenta. The first and second perfusion solutions, which contain stem cells from the placenta, are then collected in a second collection.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: January 29, 2019
    Inventor: Robert A. Dracker
  • Methods of cell separation
    Patent number: 10190091
    Abstract: The present invention relates to the use of a combination of: (i)a macromolecular erythrocyte sedimentation enhancer, and (ii) dimethyl sulphoxide (DMSO), dimethylglycine (DMG) and/or valine; to recover non-erythrocyte blood cells from a blood cell-containing sample and/or to prime non-erythrocyte blood cells to protect their integrity in subsequent cryopreservation step(s).
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: January 29, 2019
    Assignee: CELLS 4 LIFE GROUP LLP
    Inventor: Jeffrey Drew
  • Methods and systems for recovering phosphorus from wastewater including digestate recycle
    Patent number: 10189711
    Abstract: Methods and systems for removal and recovery of phosphorus from wastewater and producing inorganic phosphorus complexes including digestate recycle.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: January 29, 2019
    Assignee: Multiform Harvest Inc.
    Inventor: Keith E. Bowers
  • Diagnosis of liver pathology through assessment of anti-gal IgG glycosylation
    Patent number: 10180436
    Abstract: Methods for diagnosing pathology of the liver in subject suspected of having such pathology by measuring the glycosylation of anti-gal IgG in various biological fluids of the subject.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: January 15, 2019
    Assignee: Drexel University
    Inventors: Timothy M. Block, Mary Ann Comunale, Anand Mehta
  • Composition for improving stability of stem cells
    Patent number: 10172347
    Abstract: The present invention relates to a composition capable of improving storage stability of stem cells. More specifically, the present invention relates to a composition which contains a serum or a plasma for improving cold storage stability of stem cells. The composition for improving storage stability of stem cells according to the present invention can maintain a survival rate of over 90% for at least 9 days without changes in the properties, the number or the size of the stem cells, and thus is useful in the long-term transport of stem cells for cell therapy and the preparation of cell therapeutics injection products having an excellent effect.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: January 8, 2019
    Inventor: Jeong Chan Ra
  • Enhanced stem cell composition
    Patent number: 10172888
    Abstract: The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: January 8, 2019
    Assignee: Fate Therapeutics, Inc.
    Inventors: Daniel Shoemaker, David Robbins, John D. Mendlein, Caroline Desponts
  • Medium, for culturing corneal endothelial cells, containing conditioned medium from mesenchymal stem cells
    Patent number: 10174284
    Abstract: [Problem] To provide, in order to manufacture cells to transplant into patients with corneal endothelial failure, a medium used to culture corneal endothelial cells obtained from human corneal tissue and grow said cells while maintaining the morphology thereof as corneal endothelial cells. [Solution] A medium containing a conditioned medium from mesenchymal stem cells; and a method in which said medium is used to culture corneal endothelial cells.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: January 8, 2019
    Assignees: JCR PHARMACEUTICALS CO., LTD., THE DOSHISHA, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Michio Hagiya, Kiwamu Imagawa, Yuuki Hosoda, Noriko Koizumi, Naoki Okumura, Makiko Nakahara, Shigeru Kinoshita
  • Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
    Patent number: 10166254
    Abstract: The present invention relates to methods for treating and preventing graft-versus-host disease (GVHD) and radiation-induced tissue damage or organ failure. More particularly, methods of the present invention comprise administering a therapeutically effective amount of mesenchymal stem cell-educated macrophages (MEMs) to a subject to treat or prevent GVHD, bone marrow failure, radiation-induced tissue damage or organ failure, or a condition associated with aberrant inflammation.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: January 1, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peiman Hematti, Myriam N. Bouchlaka, Christian M. Capitini
  • Method for manufacturing an immune cell-containing composition, and a cancer-treating composition
    Patent number: 10160952
    Abstract: To provide a method in which mononuclear cells are differentiated into a good balance of NK cells, NKT cells, and T cells, and said cells are made to proliferate. The present invention provides a method for manufacturing an immune cell-containing composition, said method including the following steps: a first step in which mononuclear cells are cultured in a medium containing anti-CD16 monoclonal antibodies and either IL-2 and/or IL-15; and a second step, after the first step, in which culturing is performed under conditions that make the mononuclear cells preferentially differentiate into cytotoxic T cells. This method may also include a third step, after the second step, in which culturing is performed in a medium containing anti-CD16 monoclonal antibodies and either IL-2 and/or IL-15.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: December 25, 2018
    Inventors: Hiroyuki Abe, Seiichi Yusa
  • Methods for extracellular vesicle isolation and selective removal
    Patent number: 10160964
    Abstract: Disclosed is a method for the isolation of extracellular vesicles, including exosomes, from a liquid sample, the method comprising the steps of: adjusting the pH of a liquid sample comprising extracellular vesicles to a preselected, binding pH; contacting the liquid sample with silicon carbide, wherein at the preselected, binding pH, the extracellular vesicles bind to the silicon carbide; and eluting the bound extracellular vesicles from the silicon carbide. The liquid samples can comprise bodily fluids. Further disclosed is a method for producing a liquid sample, substantially depleted of extracellular vesicles, including exosomes.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: December 25, 2018
    Assignee: Norgen Biotek Corp.
    Inventor: Yousef Haj-Ahmad
  • Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation
    Patent number: 10144914
    Abstract: In the present specification and claims, three modified cell culture substrates are disclosed for protecting peptide mimetic surfaces used in cell culture technology. The methods are able to retain the functionality of the bioactive species conjugated to the surface. In particular, a vitronectin peptide fragment Ac-Lys-Gly-Gly-Pro-Gln-Val-Thr-Arg-Gly-Asp-Val-Phe-Thr-Met-Pro-NH2 was able to facilitate growth and proliferation of undifferentiated human embryonic stem cells after stabilization using 3 different modified cell culture substrates for of protection against gamma irradiation.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: December 4, 2018
    Assignee: Corning Incorporated
    Inventors: Dana Craig Bookbinder, Arthur Winston Martin, Santona Pal, Christopher Bankole Shogbon, Jennifer L. Weber, Yue Zhou
  • Methods for epicardial differentiation of human pluripotent stem cells
    Patent number: 10131878
    Abstract: Methods for generating high-yield, high-purity epicardial cells are described. Wnt/?-catenin signaling is first activated in human cardiac progenitor cells, by, for example, inhibiting Gsk-3 to induce differentiation into epicardial cells. Methods for long-term in vitro maintenance of human cardiac progenitor cell-derived epicardial cells and method comprising chemically defined, xeno-free, and albumin-free culture conditions are also provided.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: November 20, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Sean P. Palecek, Xiaoping Bao, Xiaojun Lian
  • Method for tissue sample fixation
    Patent number: 10126216
    Abstract: An aldehyde fixative solution at a first temperature is caused to contact a tissue sample for a first time period, additionally an aldehyde fixative solution is caused to contact the tissue sample at a second temperature higher than the first temperature for a second time period. The first time period typically ranges from about 15 minutes up to about 4 hours, and the first temperature typically is from greater than 0° C. to at least 15° C. The second temperature typically is from greater than about 22° C. to about 55° C., and the second time period ranges from about 1 hour to about 4 hours. Using this process, improved tissue morphology and IHC staining as well as superior preservation of post-translation modification signals have been accomplished in approximately 4 hours compared to 24 hours for room temperature protocols, and more even morphology and antigen preservation are observed.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: November 13, 2018
    Assignee: Ventana Medical Systems, Inc.
    Inventors: David Chafin, Abbey Pierson Theiss, Michael Otter, Esteban Roberts